Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

Kisspeptin-10 and The Central Nervous System and Hypothalamus

Kisspeptin-10 and The Central Nervous System and Hypothalamus by Dr. Usman | May 19, 2023 | Research Contents: Conclusion References Featured Product Kisspeptin-10 Peptide and The Gonadotropic Axis Kisspeptin-10 appears to potentially play a complex role in Gn

By Recovery & Performance Peptides Editorial Team

Kisspeptin-10 and The Central Nervous System and Hypothalamus

by Dr. Usman | May 19, 2023 | Research

Contents:

Conclusion

References

Featured Product

Kisspeptin-10 Peptide and The Gonadotropic Axis

Kisspeptin-10 appears to potentially play a complex role in GnRH-producing hypothalamic cells. Researchers were investigating the potential impact of Kisspeptin-10 (KP-10) on gene expression in different types of hypothalamic cell lines.[2] They suggested that in mHypoA-50 AVPV cells, Kisspeptin-10 may increase Kiss-1 mRNA and kisspeptin protein levels, possibly without affecting GnRH expression. In mHypoA-55 ARC cells, both kisspeptin genes and GnRH expression may be upregulated by Kisspeptin-10 peptide stimulation. Furthermore, Kisspeptin-10 appeared to elevate c-Fos protein levels, indicating potential neuronal activity in both cell lines. Similar apparent responses were observed in primary cultures of fetal rat neuronal cells.

Studies also suggest that Kisspeptin-10 may stimulate GnRH release in pre-pubescence and pubescence.[3] Researchers have reported that there appeared to be a significant remodeling of the native kisspeptin and neurokinin B (NKB) signaling pathways when exposed to Kisspeptin-10. In fact, Kisspeptin-10 may interact with GnRH release via both NKB neurons and kisspeptin neurons. They also comment that there may be “a parallel increase in kisspeptin release and GnRH release during puberty.” Yet, the peptide did not appear to have any initiation potential regarding pubescence.

Researchers have also aimed to investigate the potential impact of Kisspeptin-10 on the production of progesterone (P4) in bovine granulosa cells (BGCs) and the role of microRNA 1246 (miR-1246) in this process.[4] The scientists hypothesized that exposing BGCs to Kisspeptin-10 may increase the levels of P4, mRNA expression of the steroidogenesis-related gene StAR, and free cholesterol content. Simultaneously, it appeared to decrease the expression of miR-1246 in BGCs. Overexpressing miR-1246 may also inhibit P4 synthesis, StAR mRNA expression, and free cholesterol content in BGCs, while under-expressing miR-1246 may reverse this impact. Furthermore, overexpressing miR-1246 counteracted the enhancing potential of Kisspeptin-10 on P4 synthesis, StAR mRNA expression, and free cholesterol content in BGCs. Conversely, under-expressing miR-1246 appeared to amplify the enhancing potential of Kisspeptin-10. The study also indicated that miR-1246 targeted the 3’UTR of StAR in BGCs, suggesting that Kisspeptin-10 peptide promotes P4 synthesis in BGCs by facilitating the transport of free cholesterol through the regulation of miR-1246/StAR expression.

Kisspeptin-10 Peptide and Cholinergic Neurons

The accommodation of amyloid-β (Aβ) and α-synuclein (α-syn) in cholinergic neurons may potentially damage them. Yet, researchers suggest that Kisspeptin-10 may bind to Aβ extracellularly and thus potentially inhibit Aβ toxicity.[5] The scientists comment that “The KP peptides inhibited the neurotoxicity of Aβ, PrP, and IAPP peptides, via an action that could not be blocked by kisspeptin-receptor (GPR-54) or neuropeptide FF (NPFF) receptor antagonists.” Based on similarities between α-syn’s non-amyloid-β component (NAC) and Aβ’s C-terminus, other researchers have also hypothesized that Kisspeptin-10 might also mitigate α-syn-induced toxicity in cholinergic neurons.[6] They conducted experiments using cholinergic cells and commented that high concentrations of Kisspeptin-10 may increase toxicity, while low concentrations may potentially reduce both wild-type and E46K mutant α-syn-induced toxicity. The computational analysis supported these findings, indicating potentially favorable binding between Kisspeptin-10 and the C-terminal residues of α-syn. Molecular dynamics simulations also suggested the Kisspeptin-10-α-syn complexes had good stability.

Scientists have continued to explore this topic, specifically whether GPR54 (the receptor for the kisspeptin gene) activation is necessary for the Kisspeptin-10 peptide binding potential to the C-terminal pockets of α-syn.[7] To investigate this, ChAT-positive SH-SY5Y neurons were engineered to overexpress wild-type or E46K mutant α-syn, and the potential impact of Kisspeptin-10 on α-syn-induced neuronal death was evaluated using flow cytometry and immunocytochemistry. Kisspeptin-10 appeared to reduce apoptosis and mitochondrial damage caused by wild-type and E46K mutant α-syn in cholinergic neurons. Interestingly, the apparent neuroprotective potential of Kisspeptin-10 remained unaffected by combined presentation with a GPR54 antagonist, kisspeptin-234 (KP-234), indicating that GPR54 activation might not be essential for Kisspeptin-10’s action. Furthermore, the researchers commented that Kisspeptin-10 reduced α-syn and choline acetyltransferase (ChAT) immunoreactivity in neurons overexpressing wild-type and E46K mutant α-syn.

Kisspeptin-10 Peptide and Orexigenic Stimuli

Scientists have aimed to explore the potential metabolic and orexigenic action of Kisspeptin-10peptide by examining its possible impact on gene expression of neuropeptide Y (NPY) and brain-derived neurotrophic factor (BDNF), as well as the levels of dopamine (DA), norepinephrine (NE), serotonin (5-hydroxytryptamine, 5-HT), dihydroxyphenylacetic acid (DOPAC), and 5-hydroxy indole acetic acid (5-HIIA) in hypothalamic cells (Hypo-E22).[8] The results suggested that Hypo-E22 cells appear to tolerate Kisspeptin-10, and it may independently increase NPY gene expression, while BDNF expression appeared inhibited. Additionally, Kisspeptin-10 appeared to reduce 5-HT and DA levels, while NE levels reportedly remained unaffected. The apparent decrease in DA and 5-HT was consistent with increased ratios of DOPAC/DA and 5-HIIA/5-HT induced by the peptide. The apparent increase in NPY expression while reducing BDNF and 5-HT activity may support the orexigenic potential of Kisspeptin-10.

Conclusion

In conclusion, Kisspeptin-10 peptide, derived from the cleavage of Kisspeptin-54, exhibits distinct characteristics compared to longer kisspeptin fragments. In vitro studies have shed light on its potential on the gonadotropic axis, cholinergic neurons, and orexigenic stimuli. Kisspeptin-10 appears to modulate gene expression and protein levels, potentially influencing neuronal activity and GnRH release. Moreover, it shows promise in mitigating the toxicity induced by amyloid-β and α-synuclein in cholinergic neurons. The peptide’s neuroprotective potential was observed independently of GPR54 activation, suggesting alternative mechanisms at play. Additionally, Kisspeptin-10 may impact gene expression and neurotransmitter levels related to its orexigenic potential.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

References

Kotani, M., Detheux, M., Vandenbogaerde, A., Communi, D., Vanderwinden, J. M., Le Poul, E., Brézillon, S., Tyldesley, R., Suarez-Huerta, N., Vandeput, F., Blanpain, C., Schiffmann, S. N., Vassart, G., & Parmentier, M. (2001). The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. The Journal of biological chemistry, 276(37), 34631–34636. https://doi.org/10.1074/jbc.M104847200

Kanasaki, H., Tumurbaatar, T., Tumurgan, Z., Oride, A., Okada, H., & Kyo, S. (2021). Mutual Interactions Between GnRH and Kisspeptin in GnRH- and Kiss-1-Expressing Immortalized Hypothalamic Cell Models. Reproductive sciences (Thousand Oaks, Calif.), 28(12), 3380–3389. https://doi.org/10.1007/s43032-021-00695-z

Garcia, J. P., Keen, K. L., Seminara, S. B., & Terasawa, E. (2019). Role of Kisspeptin and NKB in Puberty in Nonhuman Primates: Sex Differences. Seminars in reproductive medicine, 37(2), 47–55. https://doi.org/10.1055/s-0039-3400253

Guo, L., Xu, H., Li, Y., Liu, H., Zhao, J., Lu, W., & Wang, J. (2022). Kisspeptin-10 Promotes Progesterone Synthesis in Bovine Ovarian Granulosa Cells via Downregulation of microRNA-1246. Genes, 13(2), 298. https://doi.org/10.3390/genes13020298

Milton NG, Chilumuri A, Rocha-Ferreira E, Nercessian AN, Ashioti M. Kisspeptin prevention of amyloid-β peptide neurotoxicity in vitro. ACS Chem Neurosci. 2012 Sep 19;3(9):706-19. doi: 10.1021/cn300045d. Epub 2012 May 30. PMID: 23019497; PMCID: PMC3447396.

Simon, C., Soga, T., Ahemad, N., Bhuvanendran, S., & Parhar, I. (2022). Kisspeptin-10 Rescues Cholinergic Differentiated SHSY-5Y Cells from α-Synuclein-Induced Toxicity In Vitro. International journal of molecular sciences, 23(9), 5193. https://doi.org/10.3390/ijms23095193

Simon, C., Soga, T., & Parhar, I. (2023). Kisspeptin-10 Mitigates α-Synuclein-Mediated Mitochondrial Apoptosis in SH-SY5Y-Derived Neurons via a Kisspeptin Receptor-Independent Manner. International journal of molecular sciences, 24(7), 6056. https://doi.org/10.3390/ijms24076056

Orlando, G., Leone, S., Ferrante, C., Chiavaroli, A., Mollica, A., Stefanucci, A., Macedonio, G., Dimmito, M. P., Leporini, L., Menghini, L., Brunetti, L., & Recinella, L. (2018). Effects of Kisspeptin-10 on Hypothalamic Neuropeptides and Neurotransmitters Involved in Appetite Control. Molecules (Basel, Switzerland), 23(12), 3071. https://doi.org/10.3390/molecules23123071

Dr. Usman

Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.

Latest Post

BPC157: Molecular Characterization, Pleiotropic Signaling Mechanisms, and Preclinical Research

Copper Peptides: Molecular Characterization, Mechanistic Biology, and Emerging Research

Modified GRF 1-29 and GHRP-2 Peptide Blend: Receptor Pharmacology, Somatotroph Signaling, and Neuroendocrine Research

Fragment 176-191, Modified GRF 1-29, and Ipamorelin Blend: Adipose Metabolism, GH Axis Modulation, and Receptor Signaling Research

PNC-27: Structural Characterization, HDM-2-Dependent Membrane Targeting, and Selective Tumor Cell Necrosis

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosages:

Common Protocol: Subcutaneous Injection: Kisspeptin-10 is typically administered via subcutaneous injection, with dosages commonly ranging from 100 mcg to 200 mcg per injection. The frequency of administration depends on the specific therapeutic or research objectives. Cycle Length: Treatment cycles can vary based on the intended use. For reproductive health, cycles may align with natural menstrual cycles or other hormone-related patterns.
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Research Protocol Considerations

Dose and route for LH response paradigms: Intravenous Kp-10 (at doses from 0.1 to 10 nmol/kg) is the standard route for acute LH response research in human and large animal models. Subcutaneous administration is used for sustained release protocols. The LH response should be measured at 15, 30, 45, 60, and 90 minutes post-administration to capture the full peak-and-decline kinetics. Animal models for menopause research: Ovariectomised (OVX) rodents are the standard model for oestrogen deficiency in menopause research. KNDy neuron morphology (soma size, peptide expression by immunohistochemistry, Kiss1R density on GnRH neurons), vasomotor response paradigms (tail skin temperature measurement as a proxy for flush-like events), and bone density measures are established endpoints in OVX menopausal research models. Combination with NK3R pharmacology: Given that NKB is the proximate thermoregulatory trigger and kisspeptin is the GnRH pulse activator within the same KNDy circuit, research designs examining the GnRH and vasomotor aspects of menopausal HPG dysregulation should ideally assess both kisspeptin-10 and NKB signalling endpoints. Combining Kiss1R and NK3R pharmacological tools allows dissection of kisspeptin vs NKB contributions to specific circuit outputs. 🔗 Related Reading: For a comprehensive overview of Kisspeptin-10 research, mechanisms, UK sourcing, and safety data, see our Kisspeptin-10 UK Complete Research Guide 2026. 🔗 Also See: For Kisspeptin-10 research on puberty timing and HPG axis development, see our Kisspeptin-10 and Puberty Timing Research UK 2026.

RESEARCH

Kisspeptin-10 Research Protocols

In vivo systemic administration: Subcutaneous or intraperitoneal injection in rodents, dose range 1–100 nmol/kg body weight. Due to rapid degradation by serum and tissue peptidases, pulsatile administration (every 60–120 minutes) using programmable osmotic mini-pumps or repeated bolus injection is superior to continuous infusion for maintaining physiological HPG axis activation. Plasma kisspeptin measurement by kisspeptin-immunoreactive ELISA validates systemic exposure. ICV administration: For hypothalamic-specific mechanistic studies, ICV injection via chronic cannula delivers Kisspeptin-10 directly to the third ventricle (0.1–10 nmol per injection), bypassing blood-brain barrier constraints and peripheral peptidase degradation. Particularly useful for dissecting ARC versus AVPV responses using targeted microinjection. Receptor specificity controls: GPR54 antagonist peptide 234 (p234) or kisspeptin receptor knockout mice (Kiss1r−/−) confirm on-target specificity of Kisspeptin-10 effects. Any metabolic or reproductive effect of Kisspeptin-10 that is abolished in Kiss1r−/− mice or by p234 co-treatment is GPR54-mediated; residual effects suggest off-target mechanisms. Metabolic phenotyping battery: Fasting glucose, insulin, HOMA-IR; glucose tolerance test (GTT, 2g/kg glucose IP); insulin tolerance test (ITT, 0.75 U/kg insulin IP); body composition (EchoMRI); plasma lipid panel (TG, HDL-C, LDL-C); plasma kisspeptin, LH, FSH, testosterone (males)/oestradiol (females) by ELISA.

Continue reading

Related articles